We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$156M
Cap. Flow %
-39.58%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 5.44%
3 Communication Services 2.79%
4 Industrials 1.83%
5 Consumer Discretionary 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
101
DELISTED
Ignyta, Inc.
RXDX
$117K 0.03%
+22,065
New +$129K
ABUS icon
102
Arbutus Biopharma
ABUS
$857M
$54K 0.01%
22,000
-278,000
-93% -$809K
AAPL icon
103
CALL
Apple
AAPL
$4.54T
– –
-74,000
Closed -$2.76M
ACAD icon
104
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-125,000
Closed -$3.98M
ACIU icon
105
AC Immune
ACIU
$223M
– –
-79,800
Closed -$1.31M
AMGN icon
106
Amgen
AMGN
$208B
– –
-65,900
Closed -$11M
ARWR icon
107
Arrowhead Research
ARWR
$11.9B
– –
-100,000
Closed -$735K
BIIB icon
108
Biogen
BIIB
$30B
– –
-50,000
Closed -$15.7M
BMRN icon
109
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-80,000
Closed -$7.4M
BURL icon
110
Burlington
BURL
$23.2B
– –
-18,500
Closed -$1.5M
ELLO icon
111
Ellomay Capital Ltd
ELLO
$270M
– –
-5,653
Closed -$51K
GILD icon
112
CALL
Gilead Sciences
GILD
$162B
– –
-39,200
Closed -$3.1M
GILD icon
113
Gilead Sciences
GILD
$162B
– –
-112,700
Closed -$8.92M
HSIC icon
114
Henry Schein
HSIC
$9.77B
– –
-2,550
Closed -$163K
LLY icon
115
Eli Lilly
LLY
$1.02T
– –
-200,000
Closed -$16.1M
ORA icon
116
Ormat Technologies
ORA
$6B
– –
-7,640
Closed -$370K
PFE icon
117
Pfizer
PFE
$143B
– –
-449,649
Closed -$14.4M
VTRS icon
118
Viatris
VTRS
$20.4B
– –
-200,000
Closed -$7.62M
ALIM
119
DELISTED
Alimera Sciences
ALIM
– –
-13,381
Closed -$299K
ALPN
120
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-51,175
Closed -$1.66M
KDNY
121
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-28,000
Closed -$1.74M
ACOR
122
DELISTED
Acorda Therapeutics
ACOR
– –
-1,233
Closed -$3.09M
ENDP
123
DELISTED
Endo International plc
ENDP
– –
-150,000
Closed -$3.02M
ADXS
124
DELISTED
Advaxis Inc
ADXS
– –
-13,333
Closed -$2.14M
TRIL
125
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-132,300
Closed -$1.96M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $156M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.